Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 29 July 2025, 11:30 HKT/SGT
Share:
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains

HONG KONG, July 29, 2025 - (ACN Newswire) - On one front, Unitree is accelerating toward an IPO, aiming to become “China’s first publicly listed robotics company.” On the other, Booster Robotics has just secured a historic championship at the RoboCup World Cup. These two Chinese robotics leaders have captured industry and capital market attention across both technical and financial dimensions—and they share the same investor: Shoucheng Holdings (0697.HK).

As the robotics industry reaches a dual inflection point—commercial validation and global competition breakthroughs—Shoucheng is entering a high-momentum phase where both technology and capital returns are being realized in parallel.

Unitree’s Upcoming IPO: First Exit Dividends in Sight

On July 18, China’s securities regulator (CSRC) announced that Unitree has completed its IPO tutoring and is now preparing for official filing. As a global leader in the shipment of quadruped and humanoid robots, Unitree’s Go1 and H1 products have gained strong traction in international markets.

According to public disclosures, Shoucheng Holdings holds a 3.96% stake in Unitree through the Beijing Robotics Industry Development Investment Fund, where it serves as both GP and LP—managing the fund while also sharing in its returns. With Unitree’s IPO process underway, Shoucheng is poised to benefit from fund exits, asset revaluation, and profit-sharing. As Kang Yu, General Manager of Shoucheng’s Board Office, noted in a recent interview:

“The robotics industry is shifting from technical breakthroughs to delivery validation. Capital must move from point-based deployment to systemic enablement.”Unitree’s IPO represents a key milestone in that systemic strategy.

Booster Robotics Takes the Crown: China Wins RoboCup for the First Time

On July 20, at the 2025 RoboCup World Cup, Booster Robotics—a Shoucheng-backed company—powered the Chinese national team to dominate the competition. Its T1 and K1 humanoid robots enabled China to sweep the top three places in the Humanoid League and the top two in the Small-Size League. Tsinghua University’s “Huoshen” team won the country’s first-ever RoboCup title with Booster’s T1 robot.

Known as the “Olympics of Robotics,” RoboCup—especially the Humanoid League—is an intense test of cutting-edge capabilities in algorithms, perception, motion control, and multi-agent coordination. Booster’s performance was not just a sporting victory, but a global-level validation of China’s full-stack robotic engineering capabilities. As an early investor, Shoucheng has been a direct witness to China’s leap from “running” to “winning”—and is now bringing that technical strength into broader platform integration.

From Investor to Ecosystem Builder: Shoucheng’s Platform Value Emerges

Unitree and Booster Robotics represent two complementary success paths: one in commercialization, the other in advanced technology validation. But Shoucheng Holdings is more than just an early backer—it is actively building China’s foundational robotics platform.

Through its robotics industry fund, Shoucheng has made strategic investments in companies such as Unitree, Galaxea-AI, Noetix Robotics, DEEP Robotics, forming a comprehensive embodied intelligence ecosystem across sensing, modeling, hardware, and interaction.

Meanwhile, it has also built out a commercial infrastructure including sales and leasing platforms, in-house channels (like robotics experience centers), and developer communities—all deployed across its own real-world assets like industrial parks, airports, and parking facilities.

2025 marks the “year of delivery” for robotics, and Shoucheng is executing efficiently across both its strategic lines. Unitree’s IPO is opening an exit window, while Booster Robotics has reached new technical heights in global competition.

These two outcomes reflect the tangible success of Shoucheng’s “systematic layout + platform operations” model. Despite its strong dividend record (HK$1.1 billion in 2024, with an 8% yield) and deep positioning in robotics, Shoucheng’s current valuation remains low—its dual characteristics of “bond-like stability + tech-driven growth” are yet to be fully priced in by the market.

The robotics industry is entering a new phase—moving from spectacle to substance, from lab demos to financial statements. Shoucheng Holdings stands as one of the most representative industrial platform companies ready to capture this dividend era.

 

Shoucheng Holdings, www.shouchengholdings.com
[HKSE:0697, FRA:SHVA, OTCPK:CGEY, OTCPK:SHNHF]




Topic: IPO Sectors: PE, VC & Alternatives, Artificial Intel [AI], Automation [IoT]
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Naoris Protocol Announces Upcoming TGE for $NAORIS  
July 29, 2025 23:59 HKT/SGT
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence  
July 29, 2025 23:39 HKT/SGT
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases  
July 29, 2025 23:13 HKT/SGT
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year  
July 29, 2025 23:06 HKT/SGT
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide  
Tuesday, July 29, 2025 7:00:00 PM
Wintermar Offshore (WINS:JK) Reports 1H2025 Results  
July 29, 2025 18:56 HKT/SGT
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"  
Tuesday, July 29, 2025 1:30:00 PM
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains  
July 29, 2025 11:30 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma  
Tuesday, July 29, 2025 8:01:00 AM
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China  
July 29, 2025 04:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: